Menu
Back to Journals » International Journal of Nanomedicine » Volume 17
Thiolated Chitosan Nanoparticles as a Delivery System for Antisense Therapy: Evaluation against EGFR in T47D Breast Cancer Cells [Retraction]
Authors Talaie F, Azizi E, Dinarvand R, Atyabi F
Received 9 August 2022
Accepted for publication 9 August 2022
Published 11 August 2022 Volume 2022:17 Pages 3581—3582
Talaie F, Azizi E, Dinarvand R, Atyabi F. Int J Nanomedicine. 2011;6:1963‒1975.
The Editor and Publisher of International Journal of Nanomedicine wish to retract the published article. Concerns were raised regarding the alleged duplication of images in Figures 3 and 7. Specifically,
- Figure 3A, chitosan nanoparticles, appears to have been duplicated with a similar image for Figure 3C, DOX-NAC-C nanoparticles.
- Figure 7B 1, FBS-free RPMI, appears to have been duplicated with a similar image for Figure 7B 7, NAP-C.
- Figure 7B 4, NAC-C, appears to have been duplicated with a similar image for Figure 7B 10, Chitosan.
The authors responded to our queries but were unable to provide a satisfactory explanation for the duplicated images and the Editor requested for the article to be retracted. The authors were notified of this decision.
Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.
The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.
This retraction relates to this paper
© 2022 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.